Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 95Breast Neoplasms 12Neoplasms 7Leiomyoma 4Rare Diseases 2Polycystic Ovary Syndrome 2Neoplasm Metastasis 2Adenocarcinoma 2Uveal Melanoma 1Uterine Neoplasms 1Urogenital Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Skin Neoplasms 1Skin Diseases 1Sexual Dysfunction, Physiological 1Respiratory Tract Diseases 1Prostatic Diseases 1Primary Dysautonomias 1Premenopausal Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Compliance 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Myofibroma 1Myelodysplastic Syndromes 1Melanoma 1Lymphatic Metastasis 1Lower Urinary Tract Symptoms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

cediranib 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Prostate Adenocarcinoma × Leuprolide × Clear all
NCT04914195 2023-08-01

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Bharat Serums and Vaccines Limited

Phase 3 Completed
155 enrolled
Genitourinary

Advanced Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡